



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C07K 14/00</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/63241</b> (43) International Publication Date: 26 October 2000 (26.10.00)
(21) International Application Number: PCT/US00/10340	(74) Agents: HANLEY, Elizabeth, A. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).	
(22) International Filing Date: 17 April 2000 (17.04.00)		
(30) Priority Data: 60/129,772 15 April 1999 (15.04.99) US	(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/129,772 (CIP) Filed on 15 April 1999 (15.04.99)	<b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicants (for all designated States except US): CHIL-DREN'S MEDICAL CENTER CORPORATION [US/US]; 300 Longwood Avenue, Boston, MA 02115 (US); DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 44 Binney Street, Boston, MA 02115 (US).		
(72) Inventors; and (75) Inventors/Applicants (for US only): ASHKAR, Samy [LB/US]; Apartment 606, 12 Stoneholm Street, Boston, MA 02115 (US). WEBER, Georg [-/US]; 163 Beltingham Road, Chestnut Hill, MA 02647 (US). GLIMCHER, Melvyn [-/US]; -CANTOR, Harvey [-/US] -		
(54) Title: METHODS AND COMPOSITIONS FOR MODULATING AN IMMUNE RESPONSE		
(57) Abstract		
<p>The present invention features new approaches for modulating immune responses. In particular, the invention features methods for modulating type 1 immune responses in a subject using modulators of Eta-1(early T lymphocyte activation-1)/osteopontin. Exemplary methods feature methods of treating infections, immune disorders and diseases, autoimmune disorders and diseases, various immunodeficiencies and cancer. Also provided are biosynthetic immunomodulatory molecules that include functional domains derived from Eta-1/osteopontin. Preferred biosynthetic immunomodulatory molecules include an IL-12 stimulatory domain derived from Eta-1/osteopontin or an IL-10 inhibitory domain derived from Eta-1/osteopontin. The immunomodulatory molecules of the present invention are capable of biasing an immune response in a subject towards a type 1 immune response. Accordingly, therapeutic uses are disclosed which are based on the biosynthetic immunomodulatory molecules of the present invention.</p>		